Really surprised and curious to read the article on two new concepts, one therapeutic other diagnostic.Breathtaking news that flood neurology journals were approval of a new drug Nusinersen by US FDA for childhood and adult spinal muscular atrophy, which is due to loss anterior horn cells of the spinal cord with severe disability and decreased life span. But the enthusiasm give way to the cost of therapy of more than 5crores of rs in the first year for 3-5 injections in to CSF and half the price in next year. India we cant even dream of it. Second one is in diagnosis of PD.
To differentiate between typical PD from atypical PD 's which includes MSA, PSP, and CBGD. In atypical cases serum levels of light chain of neurofibrillary filament (Nfl) is very high compared to typical PD patients, which is a great step in prognostication of parkinsonian diseases. Not yet reached India. This is…
